

12-15-06

JPW
Box 580



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor application of:

Alexander Cherkasky

Group Art Unit:

Examiner:

Serial No.: 10/577,613 ✓

Filed: October 28, 2004

For: CHERKASKY FUSION PROTEINS CONTAINING ANTIBODY,
ANTIGEN-AND MICROTUBULE-BINDING REGIONS AND
IMMUNE RESPONSE-TRIGGERING REGIONS

Attorney Docket No.: DETR 0101 PUSA

RESPONSE TO NOTIFICATION TO COMPLY
WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Amendment
Commissioner for Patents
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed October 16, 2006, Applicant hereby submits a corrected sequence listing.

CERTIFICATION UNDER 37 C.F.R. § 1.10 (EXPRESS MAIL)	
I hereby certify that this paper, including all enclosures referred to herein, is being deposited on the below date with the United States Postal Service in an envelope as 'Express Mail Post Office to Addressee' addressed to: Commissioner for Patents, U.S. Patent & Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 on:	
<u>EL 992 925 993 US</u> Express Mail Label No.	<u>James W. Proscia</u> Type or print name of person mailing paper
<u>December 14, 2006</u> Date of Deposit	<u>James W. Proscia</u> Signature

Remarks

A paper copy of the corrected sequence listing is attached.

The corrected sequence listing in computer readable form is attached.


Applicant states that the sequence listing information recorded in computer readable form is identical to the written sequence listing.

Applicant also states that the present submission does not contain new matter.

If there are any questions or concerns as to the application, the Examiner is invited to telephone the undersigned attorney so that the matter can be promptly handled.


Respectfully submitted,

Alexander Cherkasky

By 
James W. Proscia
Reg. No. 47,010
Attorney/Agent for Applicant

Date: 12/14/06

BROOKS KUSHMAN P.C.
1000 Town Center, 22nd Floor
Southfield, MI 48075-1238
Phone: 248-358-4400
Fax: 248-358-3351



RECEIVED
BROOKS KUSHMAN P.C.
2006 OCT 21 PM 3:25

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/577,613	FIRST NAMED APPLICANT Alexander Cherkasky	ATTY. DOCKET NO. DETR0101PUSA
---	--	----------------------------------

INTERNATIONAL APPLICATION NO.

PCT/IB04/03536

LA. FILING DATE 10/28/2004	PRIORITY DATE 10/28/2003
-------------------------------	-----------------------------

22045 JWP
BROOKS KUSHMAN P.C.
1000 TOWN CENTER
TWENTY-SECOND FLOOR
SOUTHFIELD, MI 48075

CONFIRMATION NO. 9743

371 FORMALITIES LETTER



OC000000020850194

Dm-12-16-06

Date Mailed: 10/16/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

TAMALA D HOLLAND

Telephone: (703) 308-9140 EXT 209

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/577,613	PCT/IB04/03536	DETR0101PUSA

FORM PCT/DO/EO/922 (371 Formalities Notice)